Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%
Joseph M Blondeau,1 Howard M Proskin,2 Christine M Sanfilippo,3 Heleen H DeCory3 1Clinical Microbiology, Royal University Hospital, Saskatoon, SK, Canada; 2Howard M. Proskin & Associates, Rochester, NY, USA; 3Pharmaceutical Medical Affairs, Bausch + Lomb, Rochester, NY, USACorrespondence: Heleen...
Guardado en:
Autores principales: | Blondeau JM, Proskin HM, Sanfilippo CM, DeCory HH |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/38f55f48aa2548318fb3802e58e6973b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
por: Silverstein BE, et al.
Publicado: (2012) -
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
por: Haas W, et al.
Publicado: (2011) -
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
por: Morris TW, et al.
Publicado: (2011) -
A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for acute viral conjunctivitis
por: Pepose JS, et al.
Publicado: (2019) -
A Review of the Differential Diagnosis of Acute Infectious Conjunctivitis: Implications for Treatment and Management
por: Yeu E, et al.
Publicado: (2020)